Latest News and Press Releases

WALTHAM, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the...

WALTHAM, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28,...

WALTHAM, Mass., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to...

WALTHAM, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that it has exceeded its 2018 financial guidance with full-year TYMLOS® U.S. net sales...

WALTHAM, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that President and Chief Executive Officer, Jesper Høiland, will present a corporate update at...

Phase 3 elacestrant study has opened for enrollmentFast Track designation from the FDA for the Phase 3 study populationElacestrant pre-clinical data demonstrates further evidence of anti-tumor...

TYMLOS® U.S. net sales continued to increase in the third quarter of 2018, totaling $27.6 million.2019 Medicare Part D coverage for TYMLOS increased from 44% to 64%  Elacestrant Phase 3 study...

WALTHAM, Mass., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 1, 2018. The Company...

WALTHAM, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing...

WALTHAM, Mass., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that Jesper Høiland, President and CEO and Charles Morris, Chief Medical Officer of the Company...